Gastrointestinal Stromal Tumors clinical trials

Explore recruiting gastrointestinal stromal tumors clinical trials.

Recruiting gastrointestinal stromal tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastrointestinal Stromal Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

France, Spain, Netherlands, Germany, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST

Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Spain, Netherlands, Norway, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Spain, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

GIST-TEN: Randomized, prospective, multicentre, open label phase II study evaluating the interest of imatinib (Glivec) treatment maintenance or interruption after at least 10 years of treatment in patients with locally advanced/metastatic Gastrointestinal Stromal Tumors (GISTs)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Germany, Spain, Sweden, Denmark, Hungary, France +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Gastrointestinal Stromal Tumors trials by city

Gastrointestinal Stromal Tumors in Toronto Gastrointestinal Stromal Tumors in Vancouver Gastrointestinal Stromal Tumors in Montreal Gastrointestinal Stromal Tumors in Calgary Gastrointestinal Stromal Tumors in Edmonton Gastrointestinal Stromal Tumors in Ottawa Gastrointestinal Stromal Tumors in Winnipeg Gastrointestinal Stromal Tumors in Quebec City Gastrointestinal Stromal Tumors in Hamilton Gastrointestinal Stromal Tumors in Kitchener Gastrointestinal Stromal Tumors in London Gastrointestinal Stromal Tumors in Halifax Gastrointestinal Stromal Tumors in New York Gastrointestinal Stromal Tumors in Los Angeles Gastrointestinal Stromal Tumors in Chicago Gastrointestinal Stromal Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease